Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04752345 Not yet recruiting - Clinical trials for ST Elevation Myocardial Infarction

Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay

Start date: March 2021
Phase: N/A
Study type: Interventional

The OPTIMAL-REPERFUSION trial will help determine whether reduced-dose facilitated PCI strategy improves clinical outcomes in patients with STEMI and anticipated PPCI delay

NCT ID: NCT04749407 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Start date: February 2021
Phase:
Study type: Observational

This study aims to dynamically monitor the expression profile status of peripheral blood mononuclear cells (PBMC) and the changes in circulating tumor DNA (ctDNA) levels in patients with stage III locally advanced unresectable non-small-cell lung cancer(NSCLC) after concurrent chemoradiotherapy or sequential chemoradiotherapy, and to explore biomarkers related to the immune microenvironment and the optimal time point for immunotherapy after chemoradiotherapy.

NCT ID: NCT04747535 Not yet recruiting - Abdominal Surgery Clinical Trials

Continuous Positive Airway Pressure After Abdominal Surgery

Start date: May 10, 2021
Phase: N/A
Study type: Interventional

This is a randomized controlled trial with an allocation ratio of 1:1. Half the patients are randomized to continuous positive airway pressure (CPAP) and half to routine medical care. Included are one hundred and twenty patients aged 18-80 years plus patients with ongoing CPAP scheduled for abdominal surgery at Umeå university hospital. The primary outcome is oxygen partial pressure (PaO2) measured on postoperative day 2 compared with the day before surgery. Secondary outcomes include diffusion capacity for carbon-monoxide, vital capacity, FEV1 and carbon-dioxide partial pressure (PaCO2) on postoperative day 2 compared with the day before surgery. PaO2 and PaCO2 are recorded from blood gas measurements obtained from the radial artery. Percentage of nocturnal hypoxia defined as the percentage of oxygen saturation during 90% of the second postoperative night. Tolerance to CPAP measured by the number of hours used CPAP. Side effects related to CPAP. All patients are examined with a simplified sleep apnea examination (Noxturnal T3, Res Med) the night before surgery. Patients in the CPAP treated group are given an auto-CPAP with a minimum pressure of 5 cm and a maximum pressure of 10 cm. They will be treated with CPAP for at least 2 hours immediately after surgery and during the first two postoperative nights. Oxygen is supplied to CPAP if oxygen saturation falls below 90%. Patients in the control group receives standard treatment and supplemental oxygen if oxygen saturation falls below 90%. In a third arm, we will include patients who already are using CPAP at night at home for previously diagnosed obstructive sleep apnea. are instructed to use CPAP for 2 hours immediately after surgery and subsequent nights during hospital stay.

NCT ID: NCT04747028 Not yet recruiting - Clinical trials for Study Focus on the Effect of Malnutrition and Dental Problem

Effect of Malnutrition on Primary and Permanent Dentation

Start date: March 2021
Phase:
Study type: Observational

The caries index delayed eruption and enamel malformation will recorded for a 2 group of participants

NCT ID: NCT04746937 Not yet recruiting - Clinical trials for Spontaneous Bacterial Peritonitis

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Start date: March 2021
Phase: Phase 3
Study type: Interventional

the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.

NCT ID: NCT04746222 Not yet recruiting - Clinical trials for Carbapenem-Resistant Enterobacteriaceae Infection

Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization

Start date: July 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Double-blinded, randomised controlled trial to evaluate the clinical efficacy of a single dose of oral capsule-administered faecal microbiota transplantation (FMT) for carbapenemase-producing Enterobacteriaceae (CPE) intestinal decolonisation compared with placebo. Primary outcome is the proportion of patients successfully decolonised of CPE intestinal carriage at 12 weeks after FMT treatment compared with placebo.

NCT ID: NCT04745598 Not yet recruiting - Clinical trials for Periodontal Disease Stage I/II/III

Impact Evaluation of Personalized Oral Hygiene Education on Periodontal Patients Stage I/II/III

HygParo
Start date: March 2021
Phase:
Study type: Observational

Evaluation of personalized oral hygiene education on plaque accumulation and gingival inflammation in periodontal patients stage I/II/III. Evaluation of personalized oral hygiene education on clinical attachment level in periodontal patients stage I/II/III. Evaluation of personalized oral hygiene education on the psychological determinants described by the Health Action Process Approach (HAPA) and the mediating role of these psychological determinants in oral hygiene habits and clinical parameters in periodontal patients stage I/II/III.

NCT ID: NCT04743297 Not yet recruiting - Induction of Labour Clinical Trials

Propess Versus Prostin for Induction of Labour in Women With Term PROM

PESTIBOR
Start date: March 2021
Phase: Phase 4
Study type: Interventional

Premature rupture of membranes (PROM) at term is a rupture that occurs at term (> 37 weeks) before the start of labor. The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor in women with term PROM Propess (Controlled release dinoprostone, Vaginal Delivery System) and Prostin E2 (Dinoprostone vaginal Tablet). Women will be randomised to two treatment groups. Although some studies support efficacy of the Propess for cervical ripening at term in induction of labor with intact membranes, it has not been well studied in women with PROM at term.

NCT ID: NCT04743115 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia, Myelodysplastic Syndrome

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS

Start date: February 2021
Phase: Phase 1
Study type: Interventional

Indication:Relapsed or refractory AML in patients for whom no established treatment options are available (this indication will heretofore be referred to as the protocol AML indication), or adult patients with MDS who are classified as high risk or very high risk according to the Revised International Prognosis Scoring System (IPSS-R). Number of Investigators and Study Centers:Up to 5 Investigators in the US. Objectives:Dose Escalation Part Primary Objective: 1. To determine the maximum tolerated dose (MTD) of BS HH 002.SA administered subcutaneously once per day for 12 days of a 28-day cycle. Secondary Objectives: 2. To provide an initial safety profile of single and multiple cycles of BS HH 002.SA. 3. To assess the pharmacokinetic (PK) profile of BS HH 002.SA. 4. To explore the anti-tumor activity of BS HH 002.SA in patients with the protocol AML indication or high-risk MDS. 5. To explore cytogenetics of the malignant cells in relation to response to BS HH 002.SA. Cohort Expansion Part Primary Objectives: 1. To evaluate safety and tolerability of BS HH 002.SA at MTD and/or lower dose level (DL) in selected cohorts of patients with the protocol AML indication or high-risk MDS. 2. To evaluate preliminary anti-tumor activity of BS HH 002.SA at MTD and/or lower DL in selected cohorts of patients with the protocol AML indication or high-risk MDS. Secondary Objectives: 3. To assess the PK profile of BS HH 002.SA. 4. To explore cytogenetics of the malignant cells in relation to response to BS HH 002.SA. Study Population:Adult patients with the protocol AML indication or high-risk MDS.

NCT ID: NCT04741971 Not yet recruiting - Quality of Life Clinical Trials

Whether Probiotics Use in Neonate and Infant Improve Their Mother's Life Quality

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

Postpartum depression and poor quality of life during postpartum were an vital issue in recent years. Infant's health condition was thought to be a possible reasons related mother's postpartum quality of life, and functional gastrointestinal disorders such as infantile colic and regurgitation were common problem during infant period. Previous study revealed that probiotics may improve the infant's discomfort caused by functional gastrointestinal disorders. Thus, this study aimed to investigate whether probiotics use in neonate and infant improve their mother's life quality?